ImmunityBio’s ANKTIVA Revenue Soars 700%, Price Target Raised to $12
Piper Sandler raised ImmunityBio's price objective to $12 from $7, citing ANKTIVA's US net revenues of $113 million in 2025 and forecasting $195 million in 2026. In the Phase 2 QUILT 2.005 trial, ANKTIVA+BCG achieved 85% six-month and 84% nine-month complete response durability versus 57% and 52% for BCG alone.
1. Piper Sandler Raises Price Objective
Piper Sandler increased ImmunityBio's price objective to $12 from $7, highlighting ANKTIVA's commercial momentum after US net revenues of $113 million in 2025. The firm forecasts ANKTIVA sales reaching $195 million in 2026, underpinning its Overweight rating and signaling stronger revenue potential.
2. Positive Phase 2 Trial Results for ANKTIVA
The Phase 2 QUILT 2.005 study enrolled 366 BCG-naïve non-muscle invasive bladder cancer patients ahead of schedule. Interim FDA review showed ANKTIVA+BCG delivered 85% complete response durability at six months and 84% at nine months, compared with 57% and 52% durability for BCG alone.
3. Outlook and BLA Submission
ImmunityBio plans to submit a biologics licensing application in the fourth quarter of 2026, aiming for regulatory approval and market launch of ANKTIVA. The combination of robust trial data and strong revenue forecasts supports the company’s valuation and potential upside for investors.